Idera Pharmaceuticals, Inc.(NASDAQ : IDRA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading IDRA News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-3.48%||80.47||1.8%||$677.67m|
|ANAC||Anacor Pharmaceuticals, Inc.||-0.14%||99.06||15.2%||$320.35m|
|REGN||Regeneron Pharmaceuticals, Inc.||-4.95%||339.48||3.1%||$301.85m|
|ALXN||Alexion Pharmaceuticals, Inc.||-8.56%||112.99||2.5%||$274.13m|
|VRTX||Vertex Pharmaceuticals Incorporated||-7.14%||81.90||2.6%||$124.14m|
|BMRN||BioMarin Pharmaceutical Inc.||-7.94%||77.01||4.0%||$117.35m|
|SRPT||Sarepta Therapeutics, Inc.||3.58%||18.52||49.4%||$116.18m|
|CPXX||Celator Pharmaceuticals, Inc.||0.13%||30.19||8.5%||$107.30m|
|A||Agilent Technologies, Inc.||-5.48%||44.12||1.0%||$94.74m|
|IONS||Ionis Pharmaceuticals, Inc.||-6.91%||21.97||8.6%||$94.46m|
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.